Actualités Regeneron Pharmaceuticals Inc - 0R2M | Actions London Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

IN BRIEF: Regeneron says second quarter results to include R&D charge

euticals Inc - Westchester, New York-based pharmaceutical company - Says it expects second quarter 2024 earnings calcu ...

EU approves Sanofi drug Dupixent for chronic lung disease

The EU has approved Sanofi's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (CO ...

Sanofi and Regeneron celebrate Dupixent's FDA approval

Sanofi SA and Regeneron Pharmaceuticals Inc on Thursday said the US Food & Drug Administration approved Dupixent as t ...

Leading pharmaceutical firms highlight positive trial data on lymphoma

A number of leading pharmaceutical companies on Monday reported positive trial results on the treatment of lymphoma, ...

Regeneron, Sanofi drug effective for young children with severe eczema

A Regeneron Pharmaceuticals Inc and Sanofi Inc new drug therapy to treat moderate to severe eczema in young children ...

Regeneron shares surge on positive Eylea trial data

Regeneron Pharmaceuticals Inc soared on Thursday after saying two trials investigating aflibercept given at a higher ...

Sanofi grants Regeneron global license for cancer treatment Libtayo

Sanofi SA on Thursday said it has agreed to assign worldwide exclusive rights to cancer drug Libtayo to partner Regen ...

US FDA accepts Regeneron and Sanofi's Dupixent for priority review

Regeneron Pharmaceuticals Inc, a New York-based biotechnology firm, and Paris-based Sanofi SA announced on Tuesday th ...

IN BRIEF: Sanofi, Regeneron hail positive results in prurigo nodularis

-based healthcare company - and Regeneron Pharmaceuticals Inc - New York-based biotechnology company - Say detailed po ...

Sanofi and Regeneron note positive new data for Dupixent

Sanofi SA and Regeneron Pharmaceuticals Inc said on Saturday that in a phase 3 trial of its monoclonal antibody Dupix ...

Regeneron and Sanofi stop trial of skin condition treatment Dupixent

Sanofi SA and Regeneron Pharmaceuticals Inc said on Friday that a phase three trial evaluating dupilumab in patients ...

Sanofi and Regeneron's Dupixent meets endpoints for skin treatment

Sanofi SA and Regeneron Pharmaceuticals Inc on Wednesday said the second phase-three trial in Dupixent, evaluating it ...

TOP NEWS: Roche and Regeneron Covid antibody cocktail approved in EU

Roche Holding AG and Regeneron Pharmaceuticals Inc's co-developed antibody cocktail was on Friday approved by the Eur ...

Sanofi and Regeneron's Dupixent trial meets primary endpoints

Sanofi SA and Regeneron Pharmaceuticals Inc said Monday the second phase 3 trial in Dupixent, evaluating its effectiv ...

US FDA accepts Regeneron's REGEN-COV application for priority review

Tarrytown, New York-based Regeneron Pharmaceuticals Inc said Thursday that its biologics license application to the U ...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regeneron Pharmaceuticals Inc (0R2M)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0R2M Actualités

IN BRIEF: Regeneron says second quarter results to include R&D charge

EU approves Sanofi drug Dupixent for chronic lung disease

Sanofi and Regeneron celebrate Dupixent's FDA approval

Leading pharmaceutical firms highlight positive trial data on lymphoma

Regeneron, Sanofi drug effective for young children with severe eczema

Regeneron shares surge on positive Eylea trial data

Sanofi grants Regeneron global license for cancer treatment Libtayo

US FDA accepts Regeneron and Sanofi's Dupixent for priority review

IN BRIEF: Sanofi, Regeneron hail positive results in prurigo nodularis

Sanofi and Regeneron note positive new data for Dupixent

Regeneron and Sanofi stop trial of skin condition treatment Dupixent

Sanofi and Regeneron's Dupixent meets endpoints for skin treatment

TOP NEWS: Roche and Regeneron Covid antibody cocktail approved in EU

Sanofi and Regeneron's Dupixent trial meets primary endpoints

US FDA accepts Regeneron's REGEN-COV application for priority review

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regeneron Pharmaceuticals Inc (0R2M) Actualités

Regeneron Pharmaceuticals Inc (0R2M)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

0R2M Actualités

IN BRIEF: Regeneron says second quarter results to include R&D charge

EU approves Sanofi drug Dupixent for chronic lung disease

Sanofi and Regeneron celebrate Dupixent's FDA approval

Leading pharmaceutical firms highlight positive trial data on lymphoma

Regeneron, Sanofi drug effective for young children with severe eczema

Regeneron shares surge on positive Eylea trial data

Sanofi grants Regeneron global license for cancer treatment Libtayo

US FDA accepts Regeneron and Sanofi's Dupixent for priority review

IN BRIEF: Sanofi, Regeneron hail positive results in prurigo nodularis

Sanofi and Regeneron note positive new data for Dupixent

Regeneron and Sanofi stop trial of skin condition treatment Dupixent

Sanofi and Regeneron's Dupixent meets endpoints for skin treatment

TOP NEWS: Roche and Regeneron Covid antibody cocktail approved in EU

Sanofi and Regeneron's Dupixent trial meets primary endpoints

US FDA accepts Regeneron's REGEN-COV application for priority review

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application